1-[(3-cyanophenyl)sulfonyl]-2-cyclopropyl-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxylic acid 1',1'-dioxide | 1448039-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[(3-cyanophenyl)sulfonyl]-2-cyclopropyl-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxylic acid 1',1'-dioxide
• 英文别名: 1-(3-cyanophenyl)sulfonyl-2-cyclopropyl-1',1'-dioxospiro[2H-indole-3,4'-thiane]-5-carboxylic acid
• CAS: 1448039-34-6
• 化学式: C₂₃H₂₂N₂O₆S₂
• 分子量: 486.569
• InChiKey: GRMBDAXGEXCAQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  149
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-[(3-cyanophenyl)sulfonyl]-2-cyclopropyl-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxylic acid 1',1'-dioxide 、 1-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]methanamine dihydrochloride 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以52%的产率得到1-[(3-cyanophenyl)sulfonyl]-2-cyclopropyl-N-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]methyl}-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxamide 1',1'-dioxide
  参考文献：
  名称：

  [EN] SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
  [FR] DÉRIVÉS DE SPIROINDOLINE POUR UNE UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HORMONE DE LIBÉRATION DES GONADOTROPHINES

  摘要：

  螺环吲哚衍生物，其制备方法及药用组合物，用于治疗疾病，并用于制造治疗疾病的药物，特别是用于治疗男性和女性的性激素相关疾病，特别是从子宫内膜异位症、子宫平滑肌瘤（纤维瘤）、多囊卵巢综合征、月经过多、经痛、多毛症、早熟、依赖性性腺类固醇的肿瘤如前列腺、乳腺和卵巢癌、促性腺激素垂体瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕、不孕症和辅助生殖疗法如体外受精等疾病组中选择的疾病。本申请特别涉及螺环吲哚衍生物作为促性腺释放激素（GnRH）受体拮抗剂。

  公开号：

  WO2014166958A1
• 作为产物：
  描述：

  一氧化碳 、 3-{[5-bromo-2-cyclopropyl-1,1'-dioxido-,2',3',5',6'-tetraahydrospiro[indole-3,4'-thiopyran]-1(2H)-yl]sulfonyl}benzonitrile 在 1,1'-双(二苯基膦)二茂铁 、 potassium acetate 、 palladium diacetate 作用下， 以 二甲基亚砜 为溶剂， 20.0~100.0 ℃ 、1.35 MPa 条件下， 反应 22.5h， 生成 1-[(3-cyanophenyl)sulfonyl]-2-cyclopropyl-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-thiopyran]-5-carboxylic acid 1',1'-dioxide
  参考文献：
  名称：

  [EN] SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
  [FR] DÉRIVÉS DE SPIROINDOLINE POUR UNE UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HORMONE DE LIBÉRATION DES GONADOTROPHINES

  摘要：

  螺环吲哚衍生物，其制备方法及药用组合物，用于治疗疾病，并用于制造治疗疾病的药物，特别是用于治疗男性和女性的性激素相关疾病，特别是从子宫内膜异位症、子宫平滑肌瘤（纤维瘤）、多囊卵巢综合征、月经过多、经痛、多毛症、早熟、依赖性性腺类固醇的肿瘤如前列腺、乳腺和卵巢癌、促性腺激素垂体瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕、不孕症和辅助生殖疗法如体外受精等疾病组中选择的疾病。本申请特别涉及螺环吲哚衍生物作为促性腺释放激素（GnRH）受体拮抗剂。

  公开号：

  WO2014166958A1

文献信息

• [EN] SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE LA SPIROINDOLINE COMME ANTAGONISTES DU RÉCEPTEUR DE L'HORMONE LIBÉRANT LA GONATROPHINE (GNRH)
  申请人：BAYER IP GMBH

  公开号：WO2013107743A1

  公开（公告）日：2013-07-25

  Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selded from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reprodudive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

  螺环吲哚衍生物，其制备方法和药物组合物，用于治疗和/或预防疾病，以及用于制造用于治疗和/或预防疾病的药物，特别是男性和女性的性激素相关疾病，尤其是来自子宫内膜异位症、子宫肌瘤、多囊卵巢综合征、多毛症、早熟、依赖性生殖腺类固醇的肿瘤如前列腺、乳腺和卵巢癌、促性腺激素垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕（例如辅助生殖治疗如体外受精）。本申请特别涉及螺环吲哚衍生物作为促性腺激素释放激素（GnRH）受体拮抗剂。
• SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS
  申请人：Bayer Intellectual Property GmbH

  公开号：US20140357655A1

  公开（公告）日：2014-12-04

  Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

  螺内酰吲哚衍生物，其制备方法和药物组合物，用于治疗和/或预防疾病，以及用于制造治疗和/或预防疾病的药物，特别是男女性激素相关疾病，尤其是选择自子宫内膜异位症，子宫肌瘤，多囊卵巢综合症，多毛症，性早熟，性腺类固醇依赖性肿瘤，如前列腺癌，乳腺癌和卵巢癌，性腺激素释放激素依赖性垂体腺瘤，睡眠呼吸暂停，肠易激综合症，经前综合症，良性前列腺增生，避孕和不育症（例如，体外受精等辅助生殖疗法）。本申请特别涉及螺内酰吲哚衍生物作为促性腺激素释放激素（GnRH）受体拮抗剂。
• SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160052936A1

  公开（公告）日：2016-02-25

  Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

  螺内酰吲哚衍生物，其制备方法和制药组合物，用于治疗疾病，以及用于制造治疗疾病的药物，特别是针对男女性激素相关疾病，尤其是在内膜异位症、子宫肌瘤（纤维瘤）、多囊卵巢综合症、月经过多、痛经、多毛症、性早熟、性腺激素依赖性肿瘤（如前列腺癌、乳腺癌和卵巢癌）、促性腺激素垂体腺瘤、睡眠呼吸暂停、肠易激综合症、经前综合症、良性前列腺增生、避孕、不孕和辅助生殖治疗（如体外受精）。本申请特别涉及作为促性腺激素释放激素（GnRH）受体拮抗剂的螺内酰吲哚衍生物。